Dendreon Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Dendreon Corporation (Dendreon) develops therapeutic vaccines to increase a patient's immune system to fight against diseases such as cancer. Provenge, the company's lead vaccine candidate, is a potential prostate cancer therapy. In addition, it is also developing vaccines to treat breast, colon, lung, ovarian, and kidney cancers, among others.

Report Highlights
Dendreon has diversified pipeline products that include: active cellular immunotherapy, monoclonal antibody and small molecule product candidates to treat a wide range of cancers. The company has collaborative partners including: Amgen, Fremont and Genentech.

Dendreon's total revenues during the period 2002-2006 declined at a CAGR of 63% from $15 million to $0.3 million. Termination of agreement with Kirin Brewery and expiry of the collaboration agreement with Johnson & Johnson Pharmaceutical research and development are the primary reasons for the significant decrease in revenues.

During 2006-2010, Dendreon's revenues are forecasted to grow at a CAGR of 66% increasing from $0.3 million to $2 million, derived primarily from the licensing granted to Wilex for small molecule inhibitors of urokinase plasminogen activator (u-PA) in developing products.
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 8
Company Financials 10
Stock Market Performance 10
P&L 12
Balance Sheet 15
Cash Flow 15
Products & Services 16
Pipeline Products 16
AC Forecast Product Sales 18
Competitors and Strategic Business Relationships 19
Key Competitors 19
Key Suppliers 19
Key Clients 20
Shareholding Structure 21
Strategy 22
Company View 22
Corporate Strategy 25
SWOT Analysis 26
Overview 26
Strengths 27
Weaknesses 28
Opportunities 29
Threats 30
Value Chain Analysis 31
Overview 31
Discovery and Product Development 32
Manufacturing 32
Scorecard 33
Overview 33
Scorecard Analysis 34
Key Employees 35
List of Employees 35
Key Employee Biographies 36
Financial and Operational Overview 43
Financial and Operational Overview 43
Appendix 45
Ask the analyst 45
Datamonitor consulting 45
Disclaimer 45
[Inhaltsverzeichnis ausblenden]

Table 1: Dendreon- Key Facts 6
Table 2: Dendreon- Year-End Share Price and Market Capitalization, 2002-2006 ($) 10
Table 3: Dendreon- Key Events Impacting Share Price Performance 11
Table 4: Dendreon- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
Table 5: Dendreon- Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
Table 6: Dendreon- Balance Sheet 15
Table 7: Dendreon- Cash Flow 15
Table 8: Dendreon- In-house Pipeline Products 16
Table 9: Dendreon- Collaboration Products 17
Table 10: Dendreon- Forecast Sales, 2006-2010 ($ Mn) 18
Table 11: Dendreon- Key Competitors 19
Table 12: Dendreon- Key Suppliers 19
Table 13: Dendreon- Key Clients 20
Table 14: Dendreon- Key Shareholders 21
Table 15: Dendreon- SWOT Analysis Summary 26
Table 16: Dendreon- Value Chain Analysis 31
Table 17: Dendreon- Scorecard 33
Table 18: Dendreon- Key Employees 35
Table 19: Dendreon - Financial and Operational Overview 43
Figure 1: Dendreon- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
[Tabellenverzeichnis ausblenden]